Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shengjia Tong"'
Autor:
Chunqi Huang, Yannan Wang, Yi Wu, Sisi Lin, Rui Hao, Jin Yu, Lu Fang, Jingjing Zhu, Di Zhao, Shengjia Tong, Yongkai Si, Tiantian Ye, Zeyu Wu, Hui Huang, Zhuoyan Wang, Ying Wang
Publikováno v:
Precision Medical Sciences, Vol 11, Iss 4, Pp 186-194 (2022)
Abstract Voriconazole is a first‐line medicine for treating invasive fungal infections. We evaluated the pharmacokinetics (PK) and safety of single/multiple doses of voriconazole injection of Hailing Pharmaceutical Group (Test, T), an imitation of
Externí odkaz:
https://doaj.org/article/24dba4c8e79a4e75901fe69d7aa46d36
Autor:
Sisi Lin, Tiantian Ye, Rui Hao, Jingjing Zhu, Yannan Wang, Di Zhao, Lu Fang, Shengjia Tong, Jin Yu, Zeyu Wu, Yongkai Si, Feifei Zhou, Yi Wu, Ying Wang, Hui Huang
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(1)
Meloxicam is an enolate nonsteroidal anti-inflammatory agent. This trial investigated the pharmacokinetics, safety, and bioequivalence of single oral doses of Aomei meloxicam (15 mg) and Mobic meloxicam (15 mg) in healthy volunteers under fasting and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7f99c9d7d7c95cd96dbca51f9c3fa7
https://pubmed.ncbi.nlm.nih.gov/34137514
https://pubmed.ncbi.nlm.nih.gov/34137514
Autor:
Chongyang Deng, Ying Wang, Hua Huang, Zeyu Wu, Jingchao Sun, Jin Yu, Yannan Wang, Sisi Lin, Yongkai Si, Shengjia Tong, Di Zhao, Lu Fang, Zhiquan Qin, Peiyuan Yan, Wu Yi, Tiantian Ye, Rui Hao, Jingjing Zhu
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(1)
Allisartan isoproxil (AI) is a blocker of the angiotensin II type 1 receptor. We evaluated the safety and pharmacokinetics of single- and multiple-dose AI in healthy Chinese individuals. Participants were assigned to receive AI or placebo. Plasma con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7dfafe99105798be30eae37fd2c3cb4
https://pubmed.ncbi.nlm.nih.gov/34240572
https://pubmed.ncbi.nlm.nih.gov/34240572
Autor:
Qigang Yang, Di Zhao, Ying Wang, Yi Wu, Lu Fang, Sisi Lin, Yannan Wang, Jin Yu, Kang Lu, Shengjia Tong, Yongkai Si, Tiantian Ye, Rui Hao, Jingjing Zhu
Publikováno v:
Clinical Pharmacology in Drug Development.
Fosaprepitant dimeglumine (FD) is a precursor of aprepitant. FD can be metabolized into aprepitant. This randomized, single-center, open, 2-cycle, single-dose, crossover bioequivalence study compared the pharmacokinetics (PK) and safety of intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbcc847b0ad32778fd260a855f977ea5
https://doi.org/10.1002/cpdd.892
https://doi.org/10.1002/cpdd.892